van Faals, Nina L.
Dekker, Iris
Balk, Lisanne J.
Moraal, Bastiaan
Barkhof, Frederik
Uitdehaag, Bernard M. J.
Killestein, Joep
Wattjes, Mike P. http://orcid.org/0000-0001-9298-2897
Funding for this research was provided by:
Stichting MS Research (14-358e)
Article History
Received: 20 March 2020
Revised: 7 June 2020
Accepted: 10 June 2020
First Online: 20 June 2020
Compliance with ethical standards
:
: N.L. van Faals, L.J. Balk, B. Moraal have nothing to disclose. I. Dekker received speaking honoraria from Roche. F. Barkhof serves as editorial board member of Brain, Neuroradiology, Neurology, Multiple Sclerosis Journal and Radiology. He has accepted personal fees from Springer, Bayer, Biogen, Roche, Apitope Ltd, IXICO ltd, Novartis, GeNEuro. Grants from Novartis, TEVA, Merck, Biogen, IMI-EU, GE Healthcare, UK MS Society, Dutch MS research foundation, NWO, NIHR. FB is supported by the NIHR UCLH biomedical research centre. B.M.J. Uitdehaag has received consultancy fees and/or research support from Biogen Idec, Sanofi Genzyme, Merck Serono, Roche and Teva. J. Killestein reports grants and personal fees from Biogen Idec, Novartis, Merck Serono, TEVA, Genzyme, Roche, outside the submitted work. M.P. Wattjes reports personal consultancy and speaking fees from Biogen, Novartis, Janssen, Roche, Celgene, IXICO, Sanofi Genzyme, Bayer Healthcare, Biologix, Genilac, Merck Serono and Teva.
: The study was approved by the Institutional review board of the VU University Medical Center, Amsterdam, The Netherlands.
: Written informed consent was obtained from all participants for the use of the clinical, laboratory and imaging data for research and teaching purposes.
: Written informed consent was obtained from all participants for publishing the data.